SAN FRANCISCO – The final day of the 2011 BIO Investor Forum started with some encouraging news: The discovery-stage deal is alive and well for biotech.In the last two months alone, BioWorld Today has reported on several deals, including Ipsen SA's multi-asset deal with Syntaxin Ltd. for botulinum toxin drugs; Merck Serono SA's potential $691 million inflammatory disease antibody collaboration with F-Star GmbH; and Merck & Co. Inc. becoming the first major commercialization partner in an early stage deal for Zymeworks Inc.'s bi-specific antibody technology.